WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update [Internet]

Excerpt

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment - Drug-Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member States on how to improve treatment and care for patients with drug-resistant TB (DR-TB). This document includes two new recommendations – one for the use of a 6-month BPaLM regimen, composed of bedaquiline, pretomanid, linezolid and moxifloxacin in patients with multidrug-resistant or rifampicin resistant TB (MDR/RR-TB) and those with additional resistance to fluoroquinolones (pre-XDR-TB) and another for a 9-month all oral regimen in patients with MDR/RR-TB and in whom resistance to fluoroquinolones has been excluded. In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB, longer all oral regimens, monitoring of treatment response, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV) and the use of surgery for patients receiving MDR-TB treatment.

The WHO Consolidated Guidelines on Tuberculosis group all DR-TB recommendations in one document and are complemented by matching modules of the consolidated operational handbook.

TB is one of the leading infectious causes of death globally. Drug-resistant TB remains a public health crisis.